Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2025
상품코드:1824454
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
호흡기세포융합바이러스(RSV) 치료제 시장 규모는 앞으로 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 23.1%로 45억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 생물학적 요법의 혁신, 새로운 항바이러스제, 노인 인구에 대한 주력, 임산부의 예방접종 전략, 세계적인 공동 연구 등에 기인하고 있습니다. 예측 기간의 주요 동향으로는 단일클론항체의 진보, 비강 백신 및 전달 시스템, 병용 요법, 신규 약물 전달 시스템, 가정 치료 옵션 등이 있습니다.
향후 5년간의 성장률 23.1%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스위스와 영국에서 수입되는 단일클론항체 예방제에 대한 접근을 제한하고, 유아 보호 프로그램을 손상시키고 신생아 의료비를 증가시킬 수 있기 때문에 미국 병원에 큰 과제가 될 수 있습니다. 또한, 상호관세와 무역마찰의 격화와 제한에 의한 세계경제와 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.
정부의 이니셔티브와 자금 제공 증가는 향후 호흡기세포융합바이러스(RSV) 치료제 시장의 성장을 뒷받침할 것입니다. RSV 치료제 개발에 대한 정부 및 건강 관리 조직의 지원은 특히 유아 및 노인과 같은 사회적 약자에서 RSV와 관련된 입원, 중증 감염, 의료비의 큰 부담을 줄일 필요성에 동기 부여됩니다. 정부 프로그램은 연구 자금 제공, 신속 승인과 같은 규제 우대 조치 및 인식을 촉진하고 조기 진단 및 치료를 장려하는 공중 보건 캠페인을 통해 RSV 치료제 분야의 확대에 기여합니다. 예를 들어, 영국 정부는 2024년 9월 유아와 노인 모두를 보호하는 세계 최초의 전국 RSV 예방접종 프로그램을 시작했습니다. 이 프로그램에는 신생아를 보호하기 위한 28주 이후의 임산부에 대한 백신, 75세 이상의 정기 프로그램, 75세부터 79세까지의 단발 캠페인이 포함됩니다. 잉글랜드, 웨일즈, 북아일랜드에서는 9월부터, 스코틀랜드에서는 8월 12일부터 시작됩니다. 이와 같이 정부의 이니셔티브와 자금 증가가 호흡기세포융합바이러스(RSV) 치료제 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 호흡기세포융합바이러스(RSV) 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 성장률 분석
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 실적 : 규모와 성장, 2019-2024
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 호흡기세포융합바이러스(RSV) 치료제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 약제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
Palivizumab
Ribavirin
기타 약
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
면역 예방
지지요법
항바이러스제
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 제형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
오랄
주사제
기타 제형
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 환자 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
소아
성인
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 세분화 Palivizumab(약제별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
단일클론항체
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 세분화 Ribavirin(약제별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
항바이러스제
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 세분화 기타 약제(약제별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
Cidofovir
Nitazoxanide
기타 실험적 또는 적응 외 치료
제7장 지역별/국가별 분석
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
호흡기세포융합바이러스(RSV) 치료제 시장 : 경쟁 구도
호흡기세포융합바이러스(RSV) 치료제 시장 : 기업 프로파일
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
AstraZeneca PLC
Abbott Laboratories
GlaxoSmithKline plc.
Gilead Sciences Inc.
Moderna Inc.
Regeneron Pharmaceuticals Inc.
Novavax AB
Vir Biotechnology Inc.
Lupin Limited
Kyorin Pharmaceutical Co. Ltd.
Bavarian Nordic A/S
SciClone Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc.
Hetero Healthcare Ltd
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
호흡기세포융합바이러스(RSV) 치료제 시장 2029 : 새로운 기회를 제공하는 국가
호흡기세포융합바이러스(RSV) 치료제 시장 2029 : 새로운 기회를 제공하는 부문
호흡기세포융합바이러스(RSV) 치료제 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Respiratory syncytial virus (RSV) therapeutics include various treatments and medications designed to manage and treat infections caused by the respiratory syncytial virus. This virus is known to cause respiratory illness, ranging from mild to severe, with higher risks for infants, young children, older adults, and individuals with weakened immune systems.
The main categories of drugs in respiratory syncytial virus (RSV) therapeutics encompass palivizumab, ribavirin, and others. Palivizumab, a monoclonal antibody developed through DNA recombination, is utilized for respiratory infections in children to prevent complications arising from respiratory syncytial virus infection. Treatments are further classified into immune prophylaxis, supportive care, and antiviral medications, available in various dosage forms such as oral, injectable, and others. These therapeutics are accessible through channels including hospital pharmacies, retail pharmacies, and online pharmacies, catering to patients ranging from pediatrics to adults.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The respiratory syncytial virus (RSV) therapeutics research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus (RSV) therapeutics market statistics, including the respiratory syncytial virus (RSV) therapeutics industry's global market size, regional shares, competitors with a respiratory syncytial virus (RSV) therapeutics market share, detailed respiratory syncytial virus (RSV) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (RSV) therapeutics industry. This respiratory syncytial virus (RSV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.6 billion in 2024 to $2 billion in 2025 at a compound annual growth rate (CAGR) of 24.6%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.
The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.
The forecast of 23.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. hospitals by restricting access to monoclonal antibody prophylactics imported from Switzerland and the UK, potentially compromising infant protection programs and increasing neonatal care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rise in government initiatives and funding is also driving the growth of the respiratory syncytial virus (RSV) therapeutics market in the future. Government and healthcare organization support for the development of RSV therapeutics is motivated by the need to alleviate the significant burden of hospitalizations, severe infections, and healthcare costs associated with RSV, particularly among vulnerable populations such as infants and the elderly. Government programs contribute to the expansion of the RSV therapeutics sector through funding for research, regulatory incentives like fast-track approvals, and public health campaigns that promote awareness and encourage early diagnosis and treatment. For instance, in September 2024, the UK Government launched the world's first national RSV vaccination program to protect both infants and older adults. This program includes vaccines for pregnant women beyond 28 weeks to safeguard newborns, a routine program for those over 75, and a one-off campaign for individuals aged 75 to 79. It aims to alleviate winter pressure on the NHS. Rollouts are set to begin in England, Wales, and Northern Ireland in September, with Scotland starting on August 12. Thus, the increase in government initiatives and funding is propelling the growth of the respiratory syncytial virus (RSV) therapeutics market.
The rising rate of disease is a key factor propelling the growth trajectory of the respiratory syncytial virus (RSV) therapeutics market. A disease signifies a pathological condition affecting a part, organ, or system of an organism due to various causes, including infection, genetic anomalies, or environmental stressors. Given RSV's widespread impact as a common respiratory virus affecting individuals across age groups, the surge in infection rates, particularly among vulnerable demographics such as infants and the elderly, underscores the urgent need for effective therapeutic interventions. For example, according to data released by the Cleveland Clinic in 2023, an estimated 57,000 children under 5 years require hospitalization annually in the U.S. due to RSV. Consequently, the escalating disease rate is a driving force behind the expansion of the respiratory syncytial virus (RSV) therapeutics market.
Developing more effective drugs and vaccines stands as a prominent trend gaining traction within the respiratory syncytial virus (RSV) therapeutics market. Key companies operating in this domain are dedicating their efforts towards creating innovative drugs and vaccines to maintain their market presence. For instance, in May 2023, Pfizer Inc., a renowned pharmaceutical manufacturer in the United States, secured approval from the Food and Drug Administration (FDA), a federal agency responsible for safeguarding public health, for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is administered to prevent lower respiratory tract illnesses caused by RSV in individuals aged 60 and above. ABRYSVO, an unadjuvanted vaccine containing a pair of preF proteins designed to enhance immunity against RSV A and B strains, has demonstrated both safety and efficacy in clinical trials.
Strategic collaborations are emerging as a significant trend gaining momentum within the respiratory syncytial virus (RSV) therapeutics market. Leading companies within this sector are prioritizing the establishment of strategic partnerships to fortify their market positions. For example, in 2023, the Cyrus Poonawalla Group, an India-based biotechnology firm, teamed up with the Serum Institute of India, a prominent biotechnology company specializing in vaccine production, to receive official regulatory clearance for a versatile vaccine. This groundbreaking vaccine aims to combat a wide spectrum of diseases, encompassing polio, tetanus, diphtheria, hepatitis B, mumps, measles, and rubella.
In June 2022, Pfizer Inc., a US-based pharmaceutical manufacturing company, successfully completed the acquisition of ReViral Limited for an undisclosed amount. This strategic move is part of Pfizer's efforts to enhance its pipeline of promising treatment candidates, with a particular focus on sisunatovir. Sisunatovir is an oral antagonist developed to prevent the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral Limited, headquartered in the UK, is a clinical-stage biotechnology company that specializes in the development of medications targeting RSV.
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the respiratory syncytial virus (rsv) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The respiratory syncytial virus (RSV) therapeutics market includes revenues earned by entities by providing services such as home care and respiratory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) therapeutics market consists of sales of antiviral drugs, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on respiratory syncytial virus (rsv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for respiratory syncytial virus (rsv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory syncytial virus (rsv) therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug: Palivizumab; Ribavirin; Other Drugs
2) By Treatment: Immune Prophylaxis; Supportive Care; Antiviral Medications
3) By Dosage Form: Oral; Injectable; Other Dosage Forms
4) By Patient Type: Pediatrics; Adults
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir; Nitazoxanide; Other Experimental Or Off-Label Treatments
3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies
4. Respiratory Syncytial Virus (RSV) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Respiratory Syncytial Virus (RSV) Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Respiratory Syncytial Virus (RSV) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Palivizumab
Ribavirin
Other Drugs
6.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Prophylaxis
Supportive Care
Antiviral Medications
6.3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Other Dosage Forms
6.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
6.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Palivizumab, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody
6.7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Ribavirin, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiviral Medication
6.8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Other Drugs, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cidofovir
Nitazoxanide
Other Experimental Or Off-Label Treatments
7. Respiratory Syncytial Virus (RSV) Therapeutics Market Regional And Country Analysis
7.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Respiratory Syncytial Virus (RSV) Therapeutics Market
9.1. China Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
9.2. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Respiratory Syncytial Virus (RSV) Therapeutics Market
10.1. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market
11.1. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
11.2. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market
12.1. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market
13.1. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market
14.1. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
14.2. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market
15.1. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
15.2. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Respiratory Syncytial Virus (RSV) Therapeutics Market
16.1. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market
21.1. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
21.2. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market
22.1. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Respiratory Syncytial Virus (RSV) Therapeutics Market
23.1. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
23.2. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Respiratory Syncytial Virus (RSV) Therapeutics Market
24.1. USA Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
24.2. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Respiratory Syncytial Virus (RSV) Therapeutics Market
26.1. South America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
26.2. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market
27.1. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market
28.1. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
28.2. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market
29.1. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
29.2. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape And Company Profiles
